{
    "clinical_study": {
        "@rank": "30289", 
        "acronym": "TACE", 
        "arm_group": [
            {
                "arm_group_label": "TACE+Sorafenib", 
                "arm_group_type": "Active Comparator", 
                "description": "TACE followed by Sorafenib"
            }, 
            {
                "arm_group_label": "TACE", 
                "arm_group_type": "Experimental", 
                "description": "TACE alone"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE)\n      followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma."
        }, 
        "brief_title": "Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients > 18 years and <=70 years of age.\n\n          -  at least 2 radiologic imaging showing characteristic features of hepatocellular\n             carcinoma  or cytologic/histologic evidence.\n\n          -  tumor in liver and radiologically definable vascular invasion or extrahepatic\n             metastasis.\n\n          -  Criteria of liver function: Child A-B level, serum bilirubin \u2264 1.5 times the upper\n             limit of normal value,alanine aminotransferase and aspartate aminotransferase \u2264 2\n             times the upper limit of normal value.\n\n          -  No dysfunction in major organs; Blood routine, kidney function, cardiac function and\n             lung function are basically normal.\n\n          -  Hb \u226590g/L,white blood cell count \u22653.000 cells/mm\u00b3,platelets \u226580.000 cells/mm\u00b3\n\n          -  Patients who can understand this trial and have signed information consent\n\n        Exclusion Criteria:\n\n          -  Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may\n             affect the treatment of liver cancer.\n\n          -  Patients with other diseases which may affect the treatment mentioned.\n\n          -  Patients with a medical history of other malignant tumors.\n\n          -  Subjects participating in other clinical trials.\n\n          -  liver function:Child C.\n\n          -  no pathological evidence of hepatocellular carcinoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150317", 
            "org_study_id": "EHBHKY2013-001-08"
        }, 
        "intervention": [
            {
                "arm_group_label": "TACE+Sorafenib", 
                "description": "TACE followed by Sorafenib", 
                "intervention_name": "TACE+Sorafenib", 
                "intervention_type": "Procedure", 
                "other_name": "TACE followed by Sorafenib"
            }, 
            {
                "arm_group_label": "TACE", 
                "description": "TACE alone", 
                "intervention_name": "TACE", 
                "intervention_type": "Procedure", 
                "other_name": "TACE"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carcinoma, Hepatocellular", 
            "Chemoembolization, Therapeutic", 
            "Sorafenib"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "contact": {
                "email": "yinlei409@hotmail.com", 
                "last_name": "Ai-jun Li, M.D.", 
                "phone": "0086-021-81875531"
            }, 
            "contact_backup": {
                "email": "dermatology2008@126.com", 
                "last_name": "Lei Yin, M.D.", 
                "phone": "0086-021-81875532"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200438"
                }, 
                "name": "Eastern Hepatobiliary Surgery Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "yinlei409@hotmail.com", 
            "last_name": "Ai-jun Li, M.D.", 
            "phone": "0086-21-81875531"
        }, 
        "overall_contact_backup": {
            "email": "dermatology2008@126.com", 
            "last_name": "Lei Yin, M.D.", 
            "phone": "0086-21-81875532"
        }, 
        "overall_official": {
            "affiliation": "Eastern Hepatobiliary Surgery Hospital, Second Military Medical University", 
            "last_name": "Ai-jun Li, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the overall survival rate of each group", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150317"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Eastern Hepatobiliary Surgery Hospital", 
            "investigator_full_name": "ShenFeng", 
            "investigator_title": "vice president of the Eastern Hepatobiliary Surgery Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Eastern Hepatobiliary Surgery Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eastern Hepatobiliary Surgery Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}